

REVIION HEALTH CARE (UK) LIMITED

INTER OFFICE MEMORANDUM

near - vented forwht hll

 **Armour Pharmaceutical
Company Limited**

C0000138

 **BERK**
Pharmaceuticals Ltd.

TO : P. Harris
FROM : C.R. Bishop
SUBJECT : NEW SCIENTIST ARTICLE

R. B. C.

25 APR 1986

DATE: 25th April 1986.

REF: CRB/BAK

COPIES TO :

A. Sheppard
R.B. Christie
M
Day
File

Thank you for your memo of the 18th April and although I appreciate the comments you make, I would request again your action.

The article states "far less than Elstree recommends as safe". Bear in mind that the article relates to the AIDS virus and not the NANB and, therefore, I am sure you wish to disagree with this statement.

I think it would also be relevant to comment on the statement they make "the problem of lengthening the time and increasing the temperature is that more and more of the final product is lost".

Of course, yield is one consideration but the major consideration must be the possible denaturation of the product and potential formation of immune complexes etc. could arise as a result of infusion of denatured products.

On the basis of the foregoing, I would again recommend that we write to the New Scientist and also to Dr. Richard Lane to get an official statement from them that they do not consider their product any safer than ours in terms of inactivation of the HTLV-III virus.

GRO-C

C.R. Bishop.